Advertisement

Ad promo image large
  • Published Date

    September 16, 2019
    This ad was originally published on this date and may contain an offer that is no longer valid. To learn more about this business and its most recent offers, click here.

Ad Text

Join us for a presentation about a treatment for hereditary ATTR (HATTR) amyloidosis Alnylam PHARMACEUTICALS ABOUT THE PROGRAM You are invited to join us to learn more about a treatment for the polyneuropathy of hATTR amyloidosis in adults. There is no cost to attend this event. Dinner and refreshments will be provided. THIS PROGRAM FEATURED PROGRAM WILL COVER: Who: Ainylam Patient Education Liaison, Karen Fuecker Disease Overview joined by Ambassador, Mike, a patient lving with hATTR amyloidosis Information About a Treatment Option Where Maggiano's Little Italy 240 Oakbrook Center Resources Oak Brook, IL 60523 When: and Support Tuesday, September 24, 2019 6:00 PM CT REGISTER NOW! hatrpatientevents.com/2657-150 OR CALL 1-877-871-0967 This program is intended for people interested in learning about hATTR amyloidosis, including individuals diagnosed with hATTR amyloidosis, their families, and caregivers 2019 Alnylam Pharmaceuticals, Inc. All rights reserved. TTRO2-USA-00154 Join us for a presentation about a treatment for hereditary ATTR (HATTR) amyloidosis Alnylam PHARMACEUTICALS ABOUT THE PROGRAM You are invited to join us to learn more about a treatment for the polyneuropathy of hATTR amyloidosis in adults. There is no cost to attend this event. Dinner and refreshments will be provided. THIS PROGRAM FEATURED PROGRAM WILL COVER: Who: Ainylam Patient Education Liaison, Karen Fuecker Disease Overview joined by Ambassador, Mike, a patient lving with hATTR amyloidosis Information About a Treatment Option Where Maggiano's Little Italy 240 Oakbrook Center Resources Oak Brook, IL 60523 When: and Support Tuesday, September 24, 2019 6:00 PM CT REGISTER NOW! hatrpatientevents.com/2657-150 OR CALL 1-877-871-0967 This program is intended for people interested in learning about hATTR amyloidosis, including individuals diagnosed with hATTR amyloidosis, their families, and caregivers 2019 Alnylam Pharmaceuticals, Inc. All rights reserved. TTRO2-USA-00154